glp 1 alzheimer's study A doctor explains why GLP-1 weight loss medications may do more than change the scale—early research suggests they could sharply cut risk by easing inflammation and protecting the brain GLP-1 and the Degenerating Brain:

Bradycardia-induced heart failure with preserved ejection fraction successfully treated with empagliflozin and theophylline: a case report

A detailed cover letter from your prescriber referencing each state requirement significantly improves approval odds

Obesity is linked to several comorbidities, such as diabetes and heart failure

The lawsuits claim that Novo Nordisk failed to warn patients and the medical community about the risk of NAION, despite growing evidence from multiple studies

GLP-1 medications act just like your body's own GLP-1: controlling blood sugar, reducing appetite, and slowing stomach emptying

Expert consensus suggests considering pharmacotherapy when there is: Significant weight regain from nadir weight BMI 27 kg/m with obesity-related comorbidities or BMI 30 kg/m Absence of anatomical complications requiring surgical revision Adequate adherence to nutritional and behavioral recommendations Patient willingness to engage in long-term pharmacotherapy The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) guidelines emphasize that pharmacologic therapy should complement, not replace, lifestyle interventions and ongoing bariatric surgical follow-up